$3.84
+0.25 (+6.96%)
Open$3.65
Previous Close$3.59
Day High$3.98
Day Low$3.65
52W High$14.38
52W Low$5.65
Volume—
Avg Volume421.7K
Market Cap199.22M
P/E Ratio37.00
EPS$0.26
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+212.8% upside
Current
$3.84
$3.84
Target
$12.01
$12.01
$8.14
$12.01 avg
$13.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 368.79M | 346.38M | 334.67M |
| Net Income | 5.96M | 4.54M | 4.70M |
| Profit Margin | 1.6% | 1.3% | 1.4% |
| EBITDA | 7.81M | 7.32M | 6.13M |
| Free Cash Flow | 4.41M | 4.25M | 6.96M |
| Rev Growth | +17.9% | -7.3% | +7.0% |
| Debt/Equity | 0.83 | 0.86 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |